Mass balance, pharmacokinetics and metabolism of [14C] BMS-582664 [brivanib] prodrug of BMS-540215, in subjects with advanced or metastatic solid tumors.
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2008
At a glance
- Drugs Brivanib alaninate (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 04 Nov 2008 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
- 04 Nov 2008 Status changed from recruiting to completed.
- 04 Nov 2008 Actual patient number (4) added as reported by ClinicalTrials.gov.